Verseon

Drugs & Health

Overview

Verseon was founded in 2002. Its proprietary drug discovery platform, developed entirely in-house, is the product of over ten years of research and development.

Features

The company’s platform is the first systematic, computationally-driven solution to achieve the molecular modelling accuracy necessary for rapid and cost-effective drug discovery. Verseon plans to use its platform to establish a diversified discovery pipeline across multiple disease areas. Current drug programs include anticoagulation, diabetic macular edema, hereditary angioedema, and oncology (solid tumors).

STO Details

Pre-sale
  • Pre-sale start date TBA
  • Pre-sale end date TBA
  • Pre-sale token supply
Token Sale
  • STO start date TBA
  • STO end date TBA
  • STO token supply
  • Soft cap TBA
  • Hard cap size TBA
Token details
  • Ticker VIAT
  • Type ERC20
  • Additional Token Emission No
  • Accepted Currencies
  • Token distribution Smart Contract
Legal
  • Country Limitations
  • Registration Country United States
  • Registration Year 2002
Rating Review and Analytics
  • Investment Rating
  • Traction Low
  • Risk Score
Verseon Contacts
TBA TBA
  • Start STO TBA
  • End STO TBA
  • Funding type
  • Token VIAT
  • Price
  • Minimum investment
  • Product Type Digital Asset
  • KYC Yes

STOs that might interest you

View All →

  • Status Ended 50 days before
  • Traction Low
  • Risk Score
  • Registration Year 2019
  • Status TBA
  • Traction Low
  • Risk Score
  • Registration Year 2014
  • Status TBA
  • Traction Low
  • Risk Score
  • Registration Year 2018

Be the First to Get New Ratings